

IN THE HOUSE OF REPRESENTATIVES

HOUSE BILL NO.

BY

AN ACT

RELATING TO UNIFORM CONTROLLED SUBSTANCES; AMENDING SECTION 37-2709, IDAHO CODE, TO \_\_\_\_\_; AND, AMENDING SECTION 37-2711, IDAHO CODE, TO \_\_\_\_\_.

Be It Enacted by the Legislature of the State of Idaho:

SECTION 1: That Section 37-2709, Idaho Code, be, and the same is hereby amended to read as follows:

37-2709. Schedule III. (a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

(b) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, (whether optical or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in schedule II which compounds, mixtures, or preparations were listed as excepted compounds under 21 CFR 1308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances.

(2) Benzphetamine;

(3) Chlorphentermine;

(4) Clortermine;

(5) Phendimetrazine.

(c) Depressants. Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(1) Any compound, mixture or preparation containing:

- i. Amobarbital;
  - ii. Secobarbital;
  - iii. Pentobarbital or any salt thereof and one (1) or more other active medicinal ingredients which are not listed in any schedule.
- (2) Any suppository dosage form containing:
- i. Amobarbital;
  - ii. Secobarbital;
  - iii. Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.
- (3) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof, including, but not limited to:
- i. Aprobarbital;
  - ii. Butobarbital (secbutabarbital);
  - iii. Butalbital;
  - iv. Butobarbital (butethal);
  - v. Talbutal;
  - vi. Thiamylal;
  - vii. Thiopental;
  - viii. Vinbarbital.
- (4) Chlorhexadol;
- (5) Embutramide;
- (6) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug, and cosmetic act;
- (7) Ketamine, its salts, isomers, and salts of isomers-7285. (Some other names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone).
- (8) Lysergic acid;
- (9) Lysergic acid amide;
- (10) Methyprylon;
- (11) Sulfondiethylmethane;
- (12) Sulfonethylmethane;
- (13) Sulfonmethane;
- (14) Tiletamine and zolazepam or any salt thereof.
- (d) Nalorphine.
- (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule:
- (1) Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

- (i) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
- (ii) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts;
- (iii) Not more than 300 milligrams of dihydrocodeinone, commonly known as hydrocodone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
- (iv) Not more than 300 milligrams of dihydrocodeinone, commonly known as hydrocodone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts;
- (v) Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts;
- (vi) Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one (1) or more ingredients in recognized therapeutic amounts;
- (vii) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts;
- (viii) Not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:

- (i) Buprenorphine.
- (ii) [Reserved].

(f) Anabolic steroids and human growth hormones. Any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins and corticosteroids) that promotes muscle growth including any salt, ester or isomer of a drug or substance listed in this paragraph, if that salt, ester or isomer promotes muscle growth.

- (1) 13beta-ethyl-17beta-hydroxygon-4-en-3-one;
- (2) 17alpha-methyl-3alpha, 17beta-dihydroxy-5alpha-androstane;
- (3) 17alpha-methyl-3beta, 17beta-dihydroxy-5alpha-androstane;
- (4) 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene;
- (5) 17alpha-methyl-4-hydroxynandrolone;
- (6) 17alpha-methyl-delta1-dihydrotestosterone;

- (7) 19-nor-4-androstenediol;
- (8) 19-nor-4-androstenedione;
- (9) 19-nor-4,9(10)-androstadienedione;
- (10) 19-nor-5-androstenediol;
- (11) 19-nor-5-androstenedione;
- (12) 1-androstenediol;
- (13) 1-androstenedione;
- (14) 3alpha,17beta-dihydroxy-5alpha-androstane;
- (15) 3beta,17beta-dihydroxy-5alpha-androstane;
- (16) 4-androstenediol;
- (17) 4-androstenedione;
- (18) 4-hydroxy-19-nortestosterone;
- (19) 4-hydroxytestosterone;
- (20) 5-androstenediol;
- (21) 5-androstenedione;
- (22) Androstenedione;
- (23) Bolasterone;
- (24) Boldenone;
- (25) Boldione;
- (26) Calusterone;
- (27) Chlorotestosterone (4-chlorotestosterone);
- (28) Clostebol;
- (29) Dehydrochlormethyltestosterone;
- (30) Delta1-dihydrotestosterone;
- (31) Desoxymethyltestosterone;
- (32) Dihydrotestosterone (4-dihydrotestosterone);
- (33) Drostanolone;
- (34) Ethylestrenol;
- (35) Fluoxymesterone;
- (36) Formebolone;
- (37) Furazabol;
- (38) Human growth hormones;
- (39) Mestanolone;
- (40) Mesterolone;
- (41) Methandienone;
- (42) Methandranone;
- (43) Methandriol;
- (44) Methandrostenolone;
- (45) Methasterone (2a, 17a-dimethyl-5a-androstan-17 $\beta$ -ol-3-one)

(~~456~~) Methenolone;  
(~~467~~) Methyldienolone;  
(~~478~~) Methyltestosterone;  
(~~489~~) Methyltrienolone;  
(~~4950~~) Mibolerone;  
(~~501~~) Nandrolone;  
(~~512~~) Norbolethone;  
(~~523~~) Norclostebol;  
(~~534~~) Norethandrolone;  
(~~545~~) Normethandrolone;  
(~~556~~) Oxandrolone;  
(~~567~~) Oxymesterone;  
(~~578~~) Oxymetholone;  
(59) Prostanazol (17 $\beta$ -hydroxy-5 $\alpha$ -androstanol[3,2-c]pyrazole)  
(~~5860~~) Stanolone;  
(~~5961~~) Stanozolol;  
(~~602~~) Stenbolone;  
(~~613~~) Testolactone;  
(~~624~~) Testosterone;  
(~~635~~) Testosterone cypionate;  
(~~646~~) Testosterone enanthate;  
(~~657~~) Testosterone propionate;  
(~~668~~) Tetrahydrogestrinone;  
(~~679~~) Trenbolone.

Anabolic steroids that are expressly intended for administration through implants to cattle or other nonhuman species, and that are approved by the federal Food and Drug Administration for such use, shall not be classified as controlled substances under this act and shall not be governed by its provisions.

In addition to the penalties prescribed in article IV of the uniform controlled substances act, any person shall be guilty of a felony who prescribes, dispenses, supplies, sells, delivers, manufactures or possesses with the intent to prescribe, dispense, supply, sell, deliver or manufacture anabolic steroids or any other human growth hormone for purposes of enhancing performance in an exercise, sport or game or hormonal manipulation intended to increase muscle mass, strength or weight without a medical necessity as determined by a physician.

(g) Hallucinogenic substances.

(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in the federal Food and Drug Administration approved product -- 7369. (Some other names for dronabinol: (6aR-trans) -6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol).

(h) Other substances. Unless specifically excepted, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substance, including its salts:

(1) Butorphanol.

(i) The board may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in subsections (b) and (c) of this section from the application of all or any part of this act if the compound, mixture, or preparation contains one (1) or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.

SECTION 2: That Section 37-2711, Idaho Code, be, and the same is hereby amended to read as follows:

37-2711. Schedule IV. (a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(1) No more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;

(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl- 3-methyl-2-propionoxybutane).

(c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) 5[alpha]-pregnan-3[alpha]-ol-11,20-dione (Alfaxalone)

~~(2)~~ Alprazolam;

~~(23)~~ Barbital;

~~(34)~~ Bromazepam;

~~(45)~~ Camazepam;

~~(56)~~ Carisoprodol;

~~(67)~~ Chloral betaine;

~~(78)~~ Chloral hydrate;

~~(89)~~ Chlordiazepoxide;

(~~9~~10) Clobazam;  
(1~~0~~1) Clonazepam;  
(1~~4~~2) Clorazepate;  
(1~~2~~3) Clotiazepam;  
(1~~3~~4) Cloxazolam;  
(1~~4~~5) Delorazepam;  
(1~~5~~6) Diazepam;  
(1~~6~~7) Dichloralphenazone;  
(1~~7~~8) Estazolam;  
(1~~8~~9) Ethchlorvynol;  
(~~19~~20) Ethinamate;  
(2~~0~~1) Ethyl loflazepate;  
(2~~4~~2) Fludiazepam;  
(2~~2~~3) Flurazepam;  
(2~~3~~4) Halazepam;  
(2~~4~~5) Haloxazolam;  
(2~~5~~6) Ketazolam;  
(2~~6~~7) Loprazolam;  
(2~~7~~8) Lorazepam;  
(2~~8~~9) Lormetazepam;  
(~~29~~30) Mebutamate;  
(3~~0~~1) Medazepam;  
(3~~4~~2) Meprobamate;  
(3~~2~~3) Methohexital;  
(3~~3~~4) Methylphenobarbital (mephobarbital);  
(3~~4~~5) Midazolam;  
(3~~5~~6) Nimetazepam;  
(3~~6~~7) Nitrazepam;  
(3~~7~~8) Nordiazepam;  
(3~~8~~9) Oxazepam;  
(~~39~~40) Oxazolam;  
(4~~0~~1) Paraldehyde;  
(4~~4~~2) Petrichloral;  
(4~~2~~3) Phenobarbital;  
(4~~3~~4) Pinazepam;  
(4~~4~~5) Prazepam;  
(4~~5~~6) Temazepam;  
(4~~6~~7) Tetrazepam;  
(4~~7~~8) Triazolam;

(489) Quazepam;

(4950) Zaleplon;

(501) Zolpidem;

(542) Zopiclone.

(d) Fenfluramine -- Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(1) Dexfenfluramine;

(2) Fenfluramine.

(e) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Cathine ((+)-norpseudoephedrine);

(2) Diethylpropion;

(3) Fencamfamin;

(4) Fenproporex;

(5) Lorcaserin

(56) Mazindol;

(67) Mefenorex;

(78) Modafinil;

(89) Pemoline (including organometallic complexes and chelates thereof);

(910) Phentermine;

(101) Pipradrol;

(142) Sibutramine;

(123) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

(f) Other substances. Unless specifically excepted, or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:

(1) Pentazocine;

(2) Fospropofol.

(g) The board may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection (c) of this section from the application of all or any part of this act if the compound, mixture, or preparation contains one (1) or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the

potential for abuse of the substances which have a depressant effect on the central nervous system.

**STATEMENT OF PURPOSE**

**RS**

---

---

---

---

**FISCAL IMPACT**

None.

**Contact:**

Mark Johnston  
Board of Pharmacy  
(208) 334-2356